The use of carbapenems in the treatment of serious infections.
Inadequate initial antimicrobial treatment in serious infections leads to increased mortality. Achieving adequate treatment is increasingly difficult because of the increasing prevalence of multidrug-resistant (MDR) pathogens. The carbapenems are potent, broad-spectrum antibiotics that have been shown to be safe and efficacious therapies in the treatment of serious infections. This review is intended to compare the 4 major members of the carbapenem class, which include imipenem, meropenem, ertapenem, and doripenem, with other widely used antimicrobial agents in the intensive care unit (ICU). The carbapenems are potent, broad-spectrum antibiotics that have been shown to be safe and efficacious therapies in the treatment of serious infections. They provide better gram-negative coverage than other beta-lactams and are stable against extended-spectrum beta-lactamases and AmpC beta-lactamases, making them effective in the treatment of many MDR bacteria. The newly approved carbapenem, doripenem, may help preserve the utility of the carbapenem class.
Baughman
Robert P
RP
Department of Internal Medicine, University of Cincinnati Medical Center, Cincinnati, Ohio 45267, USA. Bob.baughman@uc.edu
D015780:Carbapenems / Q000493:pharmacokinetics / Q000627:therapeutic use*; D024901:Drug Resistance, Multiple, Bacterial; D007239:Infections / Q000188:drug therapy*; D007362:Intensive Care Units
D015780:Carbapenems